Supernus has boosted its position in central ... are for Parkinson's disease, while the third (Myobloc) is a botulinum toxin product for cervical dystonia and chronic sialorrhea.
Hosted on MSN23d
Cantor Fitzgerald Downgrades Supernus Pharmaceuticals (SUPN)Supernus Pharmaceuticals Background Information ... for the acute treatment of hypomobility in advanced Parkinson's disease (PD); MYOBLOC® (rimabotulinumtoxinB) for the treatment of cervical ...
In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stands against the other cash-rich small cap stocks. Small-cap stocks in the US have been under ...
Shares of Supernus slid after the company it failed to meet the primary endpoint in its Phase 2b study of SPN-820 in adults with treatment resistant depression. The stock was down 22% to $31.62 in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results